Immunotoxicology of Biopharmaceutics

作者: H.G. Haggerty , K.D. Price , J.M. Shenton

DOI: 10.1016/B978-0-08-046884-6.00629-1

关键词: BiopharmaceuticalImmune systemImmunosuppressionImmunogenicityImmunosurveillanceImmunityDiseaseBiologyImmunologyImmunotoxicology

摘要: A number of biopharmaceuticals that are marketed or in development intentionally immunomodulatory they directly suppress stimulate the immune system, while others indirectly, and sometimes unintentionally, affect system function. Regardless whether immunomodulation is intentional not, it may result adverse consequences. Molecules downmodulate responses protect against consequences a disease, but also have potential to how body protects itself infection malignancies by impairing immunosurveillance, agents help fight cancer can autoimmunity. The testing biopharmaceutical should include specialized evaluation possible immunotoxicity based on an understanding type (monoclonal antibody, fusion protein, recombinant human cytokine, etc.) its expected mechanism action. battery vitro vivo tests for evaluating available, knowledge target essential determine appropriate paradigm. Testing routine assays assess general status be incorporated into required toxicology studies stand-alone targeted specific components immunity function (e.g., susceptibility cancer). intended action, assessment immunogenicity always included due possibility eliciting response animals and/or humans, which safety concerns such as loss activity exposure, immune-complex neutralization endogenous proteins. Characterizing critical risk patients immunotoxicities resulting from immunogenicity, immunosuppression, immunostimulation.

参考文章(251)
Anne-Barbara Mongey, Evelyn V Hess, Drug insight: autoimmune effects of medications-what's new? Nature Reviews Rheumatology. ,vol. 4, pp. 136- 144 ,(2008) , 10.1038/NCPRHEUM0708
ArthurJ Matas, RichardL Simmons, JohnS Najarian, CHRONIC ANTIGENIC STIMULATION, HERPESVIRUS INFECTION, AND CANCER IN TRANSPLANT RECIPIENTS The Lancet. ,vol. 305, pp. 1277- 1279 ,(1975) , 10.1016/S0140-6736(75)92555-6
P J Bugelskil, D J Herzykl, S Rehm, A G Harmsen, E V Gore, D M Williams, B E Maleeff, A M Badger, A Truneh, S R O'Brien, R A Macial, P J Wier, D G Morgan, T K Hart, Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Human & Experimental Toxicology. ,vol. 19, pp. 230- 243 ,(2000) , 10.1191/096032700678815783
Elena M. Massarotti, Nancy Y. Liu, James Mier, Michael B. Atkins, Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy The American Journal of Medicine. ,vol. 92, pp. 693- 697 ,(1992) , 10.1016/0002-9343(92)90789-E
R. B. ASHMAN, ERIN M. BOLITHO, J. M. PAPADIMITRIOU, Patterns of resistance to Candida albicans in inbred mouse strains Immunology and Cell Biology. ,vol. 71, pp. 221- 225 ,(1993) , 10.1038/ICB.1993.25
M. B. Khazaeli, Robert M. Conry, Albert F. LoBuglio, Human immune response to monoclonal antibodies. Journal of Immunotherapy. ,vol. 15, pp. 42- 52 ,(1994) , 10.1097/00002371-199401000-00006
C. L. Hirst, A. Pace, T. P. Pickersgill, R. Jones, B. N. McLean, J. P. Zajicek, N. J. Scolding, N. P. Robertson, Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis Journal of Neurology. ,vol. 255, pp. 231- 238 ,(2008) , 10.1007/S00415-008-0696-Y
Simeone Marino, Dhruv Sud, Hillarie Plessner, Philana Ling Lin, John Chan, JoAnne L Flynn, Denise E Kirschner, Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLOS Computational Biology. ,vol. 3, pp. 1909- 1924 ,(2005) , 10.1371/JOURNAL.PCBI.0030194
P. N. FOSTER, L. K. TREJDOSIEWICZ, Impaired proliferative responses of peripheral blood B cells from splenectomized subjects to phorbol ester and ionophore. Clinical and Experimental Immunology. ,vol. 89, pp. 369- 373 ,(2008) , 10.1111/J.1365-2249.1992.TB06964.X